Publication related to RSI or an RSI staff member
The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study.
Authors
- Alvarez, G G, Alvarez GG, Ottawa Hospital Research Institute, Ottawa, Canada.; University of Ottawa, School of Epidemiology and Public Health, Ottawa, Canada.; The Ottawa Hospital Department of Medicine, Ottawa, Canada.
- Van Dyk, D, Van Dyk D, Ottawa Hospital Research Institute, Ottawa, Canada.
- Mallick, R, Mallick R, Ottawa Hospital Research Institute, Ottawa, Canada.; University of Ottawa, School of Epidemiology and Public Health, Ottawa, Canada.
- Lesperance, S, Lesperance S, Nunavut Department of Health, Iqaluit, Canada.
- Demaio, P, Demaio P, Nunavut Department of Health, Iqaluit, Canada.
- Finn, S, Finn S, Nunavut Department of Health, Iqaluit, Canada.
- Potvin, S Edmunds, Potvin SE, Nunavut Tunngavik Inc, Iqaluit, Canada.
- Patterson, M, Patterson M, Nunavut Department of Health, Iqaluit, Canada.
- Pease, C, Pease C, University of Ottawa, School of Epidemiology and Public Health, Ottawa, Canada.
- Amaratunga, K, Amaratunga K, The Ottawa Hospital Department of Medicine, Ottawa, Canada.
- Hui, C, Hui C, Children's Hospital of Eastern Ontario, Ottawa, Canada.
- Cameron, D W, Cameron DW, Ottawa Hospital Research Institute, Ottawa, Canada.; University of Ottawa, School of Epidemiology and Public Health, Ottawa, Canada.; The Ottawa Hospital Department of Medicine, Ottawa, Canada.
- Mulpuru, S, Mulpuru S, Ottawa Hospital Research Institute, Ottawa, Canada.; The Ottawa Hospital Department of Medicine, Ottawa, Canada.
- Aaron, S D, Aaron SD, Ottawa Hospital Research Institute, Ottawa, Canada.; University of Ottawa, School of Epidemiology and Public Health, Ottawa, Canada.; The Ottawa Hospital Department of Medicine, Ottawa, Canada.
- Momoli, F, Momoli F, Ottawa Hospital Research Institute, Ottawa, Canada.
- Zwerling, A, Zwerling A, University of Ottawa, School of Epidemiology and Public Health, Ottawa, Canada.
YEAR OF PUBLICATION: 2020
SOURCE: Int J Circumpolar Health. 2020 Dec;79(1):1758501. doi: 10.1080/22423982.2020.1758501.
JOURNAL TITLE ABBREVIATION: Int J Circumpolar Health
JOURNAL TITLE: International journal of circumpolar health
ISSN: 2242-3982 (Electronic) 1239-9736 (Print) 1239-9736 (Linking)
VOLUME: 79
ISSUE: 1
PAGES: 1758501
PLACE OF PUBLICATION: United States
ABSTRACT:
Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada.Methods: A prospective open-label 2-year observational postmarketing study was conducted introducing 3HP for the first time in Canada in Iqaluit followed by a program rollout in Qikiqtarjuaq, Nunavut.Results: A total of 247 people were offered 3HP, 102 in the Iqaluit postmarketing study and 145 in the Qikiqtarjuaq program roll out. Although statistical significance was not reached, more people who started treatment completed treatment in the 3HP group (Iqaluit, 60/73 (82.2%) and Qikiqtarjuaq, 89/115 (77.4%)) than in the historical control 9INHgroup (306/420 = 72.9%) (p = 0.2). Most of the adverse events in 3HP treated patients were associated with mild discomfort but no disruption of normal daily activity. Not drinking alcohol was associated with increased 3HP completion (OR 13.33, 95% CI, 2.27-78.20) as was not taking concomitant medications (OR 7.19, 95% CI, 1.47-35.30).Conclusions: The present study supports the feasibility and safety profile of 3HP for the treatment of LTBI in Nunavut.
Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada.Methods: A prospective open-label 2-year observational postmarketing study was conducted introducing 3HP for the first time in Canada in Iqaluit followed by a program rollout in Qikiqtarjuaq, Nunavut.Results: A total of 247 people were offered 3HP, 102 in the Iqaluit postmarketing study and 145 in the Qikiqtarjuaq program roll out. Although statistical significance was not reached, more people who started treatment completed treatment in the 3HP group (Iqaluit, 60/73 (82.2%) and Qikiqtarjuaq, 89/115 (77.4%)) than in the historical control 9INHgroup (306/420 = 72.9%) (p = 0.2). Most of the adverse events in 3HP treated patients were associated with mild discomfort but no disruption of normal daily activity. Not drinking alcohol was associated with increased 3HP completion (OR 13.33, 95% CI, 2.27-78.20) as was not taking concomitant medications (OR 7.19, 95% CI, 1.47-35.30).Conclusions: The present study supports the feasibility and safety profile of 3HP for the treatment of LTBI in Nunavut.
LANGUAGE: eng
DATE OF PUBLICATION: 2020 Dec
DATE COMPLETED: 20210615
DATE REVISED: 20221207
MESH DATE: 2021/06/16 06:00
EDAT: 2020/05/08 06:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: 10.1080/22423982.2020.1758501 [doi] 1758501
OWNER: NLM
Related RSI Experts
Vice-President Chemical and Product Safety
Dr. Franco Momoli joined Risk Sciences International (RSI) in 2019 and currently serves as Vice-President, Chemical and Product Safety. In this role, he leads a multidisciplinary team of epidemiologists, risk assessors, toxicologists, and biostatisticians in conducting human health risk assessments...